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Abstract Abstract Abstract Abstract       
 
The wall less bacterium Ureaplasma parvum (Up) is associated with ureathritis in 
adults and pneumonia in neonates. Up lack de novo nucleotide synthesis genes and 
has  to  import  all  DNA  precursors.  This  thesis  investigates  known  DNA 
biosynthesis pathways as targets for new antibiotics and concerns two enzymes in 
Up  thymidylate  synthesis;  a  thymidylate  synthase  (TS)  and  thymidine  kinase 
(UpTK).  
 
   TS activity was detected in Up-extracts and UU572 DNA could rescue a TS 
mutant E. coli. UU572 appeared to be proteolytic cleaved and cell cycle regulated 
in Up. Codon modified UU572 was cloned for expression in E. coli. However, no 
protein  expression  could  be  detected.  A  codon  optimized  synthesized  UU572 
homolog;  MPN358  from  Mycoplasma  pneumonia  was  expressed  in  E.  coli  and 
showed TS activity. Low sequence homology to existing TSs suggests that UU572 
and its homologs, belong to a new class of TS enzymes, which may contribute to 
future antibiotic development in human and veterinary medicine.   
   
   Thirteen click chemistry-synthesized 3´-triazole thymidine analogs (1-13), using 
AZT  as  backbone,  were  evaluated  with  UpTK  and  hTK1.  The  bacterial  TK 
exhibited a more open 3D structure than hTK1 explaining its substrate efficiency, 
while hTK1 seemed to have more closed structure as reflected by higher inhibition 
by the analogs. Docking models with 13 in TK1 structures revealed amino acid 
substitutions  in  the  active  site  and  most  likely  explain  the  different  enzyme 
specificity.  In  addition,  molecular  docking  could  explain  the  6-fold  higher 
inhibition  by  the  nucleoside  analog  3´-azido-methyl-deoxythymidine  (AZMT) 
with UpTK compared to hTK1. Nucleoside analogs have been used for fighting 
viruses with minimal side-effects. Why not use this strategy to control bacterial 
infections?  The  results  presented  in  this  thesis  contribute  towards attaining this 
goal. 
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dAK 
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Dihydrofolate reductase 
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RecA  Recombination protein A 
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TS   
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ThyA 
ThyX 
TK2 
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Thymidylate Synthase 
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Traditional thymidylate synthase 
Flavin-dependent Thymidylate synthase   
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Nucleosides/Nucleotides  
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dA 
 
 
 
Adenosine triphosphate 
deoxyadenosine   8
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dNMP 
dT 
dTTP 
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5-fluorodeoxyuridine monophosphate  
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1 1 1 1  Introduction Introduction Introduction Introduction       
1.1 1.1 1.1 1.1  The need for new alternative antimicrobial agents  The need for new alternative antimicrobial agents  The need for new alternative antimicrobial agents  The need for new alternative antimicrobial agents        
In order to survive, all living organisms strive to adapt to their environment. 
Thus,  it  should  not  be  surprising  to  us  that  bacteria  have  shown  a 
remarkable ability to endure and adapt to their environment, as they have 
done several eons before the human species appeared on Earth. The end 
results of this phenomena is that many bacteria have evolved resistance to 
almost  all  antibiotics  used  today  and  the  problem  is  highlighted  by  the 
emergence of multiple-drug resistant strains-so-called “super-bugs” (Brown, 
2006). Most classes of antibiotics were discovered during the 1940-1950s, 
and are directed against specific areas of bacterial physiology, mainly cell 
wall,  DNA  and  protein  biosynthesis.  At  that  time,  it  seemed possible to 
eradicate most of the common infectious diseases from humanity. However, 
early  signals  of  bacterial  resistance  and  warning  from  the  penicillin 
discoverer Sir Alexander Fleming confirmed that the bacterial eradication 
only was a dream. Chemical modification of existing antibiotics represents 
current antibiotic development. It is believed that widespread bacterial drug 
resistance is due to the limited choice of antibiotics and wide spread use of 
these  drugs  causing  bacterial  strain  selection  with  resistance  properties 
(Brown, 2006). What are the risk factors for the development of antibiotic 
resistance?  Overuse of antibiotics in hospitalized patients, high availability 
of  antibiotics  without  prescriptions,  large  amounts  of  antibiotics  in 
agriculture  industry,  longer  life  expectancy  with  increased  need  of 
antibiotics in elderly. Modern food animal production is heavily depended 
on  the  use  of  massive  amounts  of  antibiotics  for  animal  disease  control; 
Table 1 illustrates the use of antibiotics in production of one kilogram of 
meat in different EU-countries.    10
 
Table 1. Estimated milligram of antimicrobial agents used in 1997 per kilogram produced meat in 
different countries of the EU (Source EMEA 1999). 
 
 
This favors the selection, spread and persistence of drug resistant bacteria 
from  farm  animals  to  humans  and  products  of  animal  origin  are  traded 
worldwide. Thus, antimicrobial resistance in one country is a problem for 
all  countries  and  difficulties  in  obtaining  reliable  information  about  drug 
consumption makes it more difficult to tackle resistance problems (Brown, 
2006). This emerging drug resistance now poses a threat to both human and 
animal  health  and  should  be  taken  seriously.  Development  of  new 
antibiotics is inevitable because we are moving towards an environment of 
ever-growing numbers of new infectious diseases. The net-result could be 
increased morbidity, mortality and community cost.  
1.2 1.2 1.2 1.2  Bacteria in focus Bacteria in focus Bacteria in focus Bacteria in focus:  :  :  : Ureaplasma parvum Ureaplasma parvum Ureaplasma parvum Ureaplasma parvum       ( ( ( (Up Up Up Up) ) ) )       
The smallest free living organisms known today are bacteria belonging to 
class of Mollicutes (mollis = soft and cutis = skin), which are widespread in 
nature and involving members from the genera Mycoplasma and Ureaplasma. 
Many species from these genera are both of human and veterinary medical   
importance  (Razin  et  al.,  1998).  These  microbes  are  slow  growing 
facultative anaerobes; many species need fatty acids and cholesterol for their 
growth, as well for osmotic and morphological stability. Fastidious growth 
requirements are usually met by complex medium containing yeast extract 
and serum, however sometimes these can be toxic for the organisms. It is 
therefore difficult to identify the right species for correct clinical treatments   11
for both humans and animals (Razin et al., 1998). The bacterium Ureaplasma 
urealyticum  (Uu)  containing  14  serotypes,  was  found  in  the  human 
ureogenital tract over 50 years ago (Robertson & Stemke, 1982; Shepard, 
1956; Shepard, 1954). These are self replicating entities that grew at low pH 
with optimal growth at 6.0-6.5 and in presence of urea (Ford et al., 1962). 
After prolonged debate, the serotypes were then divided into two groups; 
biovar  1  and  biovar  2,  because  of  different  phenotypic  markers  such  as 
antigentic types, polypeptide patterns, ribosomal RNA etc. They were later 
separated into two distinct species: Ureaplasma parvum (Up) (Serovars 1,3, 6 
and  14)  with  smaller genomes and the rest of the serovars as Ureaplasma 
urealyticum (Kong & Gilbert, 2004; Robertson et al., 2002).  
 
   Up is classified as an opportunistic human pathogen found in up to 80 % 
of all adults; it colonizes urogenital tract mucosa as well as the respiratory 
tract.  Especially  in  neonates  it  is  vertical  transmitted  from  the  mother 
(Pollack,  2001).  Up  is  associated  in  a  wide  array  of  conditions  affecting 
females and males, including non-gonococcal urethritis (NGU), infertility, 
prostatitis,  spontaneous  abortion,  premature  birth,  meningitis  and  severe 
respiratory disease in newborns called bronchopulmonary dysplasia (BPD) 
(Schelonka  & Waites, 2007; Waites et al., 2005; Volgmann et al., 2005; 
Pollack, 2001; Cassell et al., 1993). Recent research in the medical field is 
concentrated  on  exploring  its  mechanisms  for  pathogenesis,  especially  its 
role  as  neonate  pathogens.  Lack  of  documentation  for  Ureaplasma 
eradication  following  completion  of  treatment  and  increased  neonate 
sensitivity for side-effects has resulted in that no specific antibiotics against 
Ureaplasma is available today. However macrolides such as erythromycin is 
the most common choice of treatment, but with varying results (Waites et 
al., 2005). Therefore there is a need for more specific anti-ureaplasma agent 
with less side-effects.  
 
   Up has a circular chromosome consisting of 750 kb and Ureaplasma like 
Mycoplasma have been exposed to degenerative evolution by significant loss 
of genome sequences (Razin et al., 1998). Common properties are the lack 
of cell wall and are thereby resistance to most common antibiotics; evolved 
from  gram  positive  bacteria  (Glass et al., 2000); high AT-ratio of ~70%; 
small genomes e.g. ~580 kb Mycoplasma genitalium (Mg); small genomes give 
rise  to  limited  biochemical  pathways  and  requires  an  host  to  obtain  all 
nutrients. This class use stop-codon UGA as tryptophan, which is usually 
recognized as a stop codon. Therefore it is extremely difficult to express 
many Mycoplasma genes using E. coli as expression system. A way to avoid   12
this  problem  is  to  use  an  E.  coli  strain  (ISM612)  with  modified  tRNA 
inserting tryptophan into UGA codons. This is widely used for studying 
Mycoplasma  proteins,  however  only  <40%  of  the  UGA  codons  are  read, 
affecting the expression levels (Minion, 1998). However, this approach is 
still not able to compensate for the AT-ratio effect, resulting in low protein 
expression.  
 
   Genome  sequencing  and  other  observations  have  surprisingly  revealed 
that Mollicutes in general exhibit limit capacity to synthesize DNA and RNA 
precursors (Vasconcelos et al., 2005; Glass et al., 2000). Almost all Mollicutes 
are unable to synthesize the DNA building blocks from scratch, therefore 
species like Ureaplasma parvum has to import all DNA precursors or have 
other converting mechanisms (Glass et al., 2000; Mitchell & Finch, 1977). 
In  addition,  Ureaplasma  also  has  the  unique  ability  to  harvest  95%  of all 
energy  by  using  urease  to  hydrolyze  urea to ammonium ion production 
(Razin et al., 1998; Smith et al., 1993).  
 
1.3 1.3 1.3 1.3  Overview of DNA precursor biosynthesis  Overview of DNA precursor biosynthesis  Overview of DNA precursor biosynthesis  Overview of DNA precursor biosynthesis        
A balanced supply of the four DNA building blocks (figure 1A) i.e. the 
deoxyribonucleoside  triphosphates  (dNTPs),  is  necessary  to  maintain  and 
transmit the genetic information to the next generation. This rule involve 
also  viruses,  however  some  have  a  RNA-  rather  than  DNA  as  genetic 
material. DNA precursors are synthesized by two pathways: the de novo or 
the salvage pathways (figure 1B).  
 
   The de novo synthesis uses different enzymes for numerous reactions with 
small  molecules  like  amino  acids,  phosphoribosylpyrophosphate  (PRPP), 
CO2, ATP and NH3 to build up ribonucleoside monophosphates (NMPs). 
These  NMPs  are  further  phosphorylated  to  ribonucleoside  diphosphates 
(NDPs),  which  can  be  reduced  to  deoxyribonucleoside  diphosphates 
(dNDPs) by the key enzyme ribonucleotide reductase (RNR), which uses 
an extraordinary protein radical for this catalytic process. Because RNR is 
rigorous allosterically and cell cycle regulated, its role as a regulator in the de 
novo  synthesis  is  vital  and  conserved  in  most  organisms  (Nordlund  & 
Reichard, 2006). 
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Figure  1.  A)  Components  of  nucleoside,  consisting  of  a  base  (either  a  purine  or 
pyrimidine),  sugar  and  phosphate-group/s  for  nucleotides.  B)  Schematic  routes  for 
nucleotide synthesis. The salvage nucleotide synthesis pathway on the left panel and de novo 
nucleotide synthesis on the right panel. Enzymes are in blue and other reactants are in 
black.  RNR  has  also  been  observed  in  NTP  to  dNTP  conversation  (Nordlund  & 
Reichard, 2006) and recently a new thymidylate synthase named ThyX was discovered (red 
box) (Myllykallio et al., 2002). 
 
Uracil,  a  non-methylated  precursor  of  thymine  is  not  a  component  of 
DNA,  therefore  an  additional  step  are  required  for  converting  uracil  to 
thymine. The synthesis of dTMP from dUMP is catalyzed by thymidylate 
synthase  (ThyA),  which  is  an  important  enzyme  conserved  in  many 
organisms (Costi et al., 2005; Costi, 1998). Recently a novel thymidylate 
synthase, ThyX was discovered (Myllykallio et al., 2002), however, no gene 
coding for ThyA or ThyX was detected in the Up genome (Glass et al., 
2000).  Previous  studies  revealed  that  phosphorylated  deoxyuridine  (dU) 
could  be  further  converted  to  dTTP  and  incorporated  into  Up  DNA 
indicating a TS activity (Carnrot et al., 2003). This activity will be further 
investigated in paper I.  
 
   The  alternative  pathway;  the  salvage  synthesis,  occurs  in  all  cells 
complementing  the  de  novo  synthesis  and  recycles  deoxyribonucleosides 
from  degraded  DNA.  The  first  phosphorylation  of  the  deoxynucleosides 
A  B   14
(dNs) is performed by deoxynucleoside kinases (dNKs). This is often the 
rate-limiting step in this pathway (Arner & Eriksson, 1995), trapping the 
negative  charged  nucleoside  within the cell. Our group showed that Up 
phosphorylated  all  natural  dexonucleosides  (Wang  et  al.,  2001).  Later 
characterization  and  structural  crystallization  revealed  two  enzymes;  a 
thymidine kinase and a deoxyadensine kinase responsible for these catalytic 
events (Welin et al., 2007; Welin et al., 2004; Carnrot et al., 2003). Just as 
in  the  de  novo  pathway,  (deoxy)ribonucleoside  monophosphate  kinases, 
(d)NMPKs and ribonucleoside diphosphate kinases (NDPKs) phosphorylate 
the last two steps giving the dNTP is used for DNA replication and repair 
(Arner & Eriksson, 1995). However no homolog of NDPKs is found in the 
Up  genome  (Glass  et  al.,  2000).  Recently,  it  was  observed  that  Up 
ribonucleoside  monophosphate  kinases  (NMPKs)  exhibited  diphosphate 
kinase  activities,  which  strongly  indicated  that  these  enzymes  could 
substitute the NDPK function in vivo (Wang, 2007).  
 
   Most organisms have both DNA precursor synthesis pathways, however 
bacteria like Ureaplasma parvum (Up) has no gene for RNR (Glass et al., 
2000) and therefore has to rely on salvage enzymes to maintain balanced 
dNTP pools for replication and repair (Carnrot et al., 2003; Wang et al., 
2001).  Free  purine  and  pyrimidine  bases  recycling  are  also  part  of  the 
salvage pathway, but will not be further described here. 
1.4 1.4 1.4 1.4  Thymidylate synthase (TS) Thymidylate synthase (TS) Thymidylate synthase (TS) Thymidylate synthase (TS)       
Thymidylate  synthase  (ThyA),  an  enzyme  with  catalytic  and  regulatory 
functions, converts dUMP by reductive methylation to a DNA precursor 
dTMP.  ThyA  was  considered  the  only  enzyme  responsible  for  de  novo 
dTMP  formation,  however  comparative  genomics  revealed  that  a  large 
number of microbial genomes apparently lack several pathways for de novo 
and salvage synthesis of dTMP (Myllykallio et al., 2002). In 1989 a gene of 
unknown  function  was  implicated  in  the  thymidine  metabolism  of 
Dictyostelium  discoideum  by  genetic  complementation  tests  (Dynes,  1989). 
Myllokallio  et  al.,  (2002)  later  proved  experimentally  that these enzymes 
possess a flavin-dependent thymidylate synthase activity both in vivo and in 
vitro, and was designated ThyX. Although both ThyA and ThyX are N5, 
N10-methylenetetrahydrofolate  (CH2H4folate)  dependant  enzymes,  they 
differ  regarding  their  reductive  mechanisms.  These  enzymes  likely  have 
different evolutionary origins, since both enzyme classes lack sequence and   15
structural  similarities  to  each  other  (figure  2)  (Mathews  et  al.,  2003; 
Myllykallio et al., 2003; Murzin, 2002; Myllykallio et al., 2002).   
 
Figure  2.  A)    Homotetramer  of  Mycobacteria  tuberculosis  ThyX  (MtThyX)  (2GQ2)  B) 
Dimer of E. coli ThyA 
1.4.1 1.4.1 1.4.1 1.4.1 Traditional thymidylate synthase (ThyA) Traditional thymidylate synthase (ThyA) Traditional thymidylate synthase (ThyA) Traditional thymidylate synthase (ThyA)       
The classical thymidylate synthase (ThyA) is active as a dimer and catalyze 
the  de  novo  production  of  dTMP  in  vivo.  The  enzymatic  step  of  dTMP 
synthesis from dUMP is conserved in most living organisms. ThyA uses N5, 
N10-methylenetetrahydrofolate  as  one-carbon  donor  and  reducing  agent 
resulting  in  dTMP  and  dihydrofolate  (H2folate)  production  (figures  3-4), 
(Costi et al., 2005; Costi, 1998).  
 
Figure 3. Schematic reaction mechanisms of different thymidylate synthases A) ThyA and 
B) ThyX.  
Reduced  folates  are  essential  for  many  biological  functions,  H2folate  is 
therefore  rapidly  reduced  by  NADPH  to  tetrahydrofolate  (H4folate)  in 
reaction  by  dehydrofolate  reductase  (DHFR)  (Myllykallio  et  al.,  2003; 
Costi, 1998).  
A  B 
   16
 
Figure  4.    Schematic  representation  of  dTMP  synthesis  in  the  dUMP-folate  cycle 
involving ThyA or ThyX (enzymes are in green). Although both produce dTMP, each 
enzyme uses a different reductive mechanism.  
DHFR is tightly coupled to ThyA, so if the ThyA gene is observed then 
there is also a DHFR gene. Both enzymes have been used widely as drug 
targets for development of antimicrobial and anticancer agents. For example 
bacterial  DHFR is specifically inhibited by trimethoprim. The anticancer 
pro-drug  5-flourouracil  (5-FU),  exerts  its  toxic  activity  in  the  
deoxyribonucleotide form (5-FdUMP); binds to ThyA and acts as a suicide 
inhibitor (figure 4), (Costi et al., 2005; Costi, 1998)  
1.4.2 1.4.2 1.4.2 1.4.2 Newly discovered thymidylate synthase  Newly discovered thymidylate synthase  Newly discovered thymidylate synthase  Newly discovered thymidylate synthase        
ThyX; a flavin-dependent thymidylate synthase, was first characterized by 
Myllykallio  et  al.,  (2002).  ThyX  genes  are  found  in  many  pathogenic 
bacteria  and  several  double  stranded  DNA  viruses  (Graziani  et al., 2006; 
Zhong et al., 2006; Griffin et al., 2005; Sampathkumar et al., 2005; Graziani 
et al., 2004; Myllykallio et al., 2003; Myllykallio et al., 2002). Its activity 
relies  on  NADH/NADPH  oxidation  and  uses  tetrahydrofolate 
(CH2H4folate)  as  one-carbon  donor  and  as  reducing  agent  pyrimidine 
nucleotide called flavin adenine dinucleotide (FADH/H2) to form dTMP   17
and tetrahydrofolate, (figure 3B) (Ulmer et al., 2008; Gattis & Palfey, 2005; 
Griffin et al., 2005; Graziani et al., 2004; Leduc et al., 2004; Myllykallio et 
al., 2002). ThyX contains the motifs -T/RHRX7-8S- and the majority of 
ThyX  proteins  are  composed  of  around  200-250  amino  acids. However 
homologues of Chlamydia (CtThyX) and Thermoplasma species are larger, 
containing  two  fused  ThyX  domains  in  the  same  protein  suggesting 
duplication  events  have  taken  place  several  times  independently 
(Sampathkumar et al., 2006; Griffin et al., 2005; Mathews et al., 2003).   
 
1.5 1.5 1.5 1.5  Thymidine kinase 1, th Thymidine kinase 1, th Thymidine kinase 1, th Thymidine kinase 1, thymidine kinase 2 and other  ymidine kinase 2 and other  ymidine kinase 2 and other  ymidine kinase 2 and other 
deoxy deoxy deoxy deoxynucleoside kinases nucleoside kinases nucleoside kinases nucleoside kinases       
The dNKs are found in a wide range of species with different quantities and 
are enzymes catalyzing the first step in the salvage pathway. In mammals, 
there  are  four  dNKs  with  overlapping  substrate  specificities  for  the  four 
DNA  precursors:  cytosolic  thymidine  kinase  1  (TK1)  phosphorylates 
thymidine (dT) and dexoxyuridine (dU); cytoplasmic deoxycytidine kinase 
(dCK)  phosphorylates  deoxycytidine  (dC),  deoxyadenosine  (dA)  and 
deoxyguanosine  (dG);  mitochondrial  deoxyguanosine  kinase  (dGK) 
phosphorylates dA and dG; and mitochondrial TK2 (TK2) phosphorylating 
both dT and dC (Eriksson et al., 2002). Many nucleoside triphosphates have 
the  ability  to  act  as  phosphate  donors,  whereas  the  universal  biological 
currency ATP is accepted by all dNKs. dNKs use a general phosphorylation 
mechanism illustrated in figure 5.  
 
Figure 5. Common catalytic reaction mechanisms for phosphate group transfer by dNKs. 
Modified illustration from (Eriksson et al., 2002).  
Usually a glutamatic acid or aspartic acid act as base and starts the reaction 
by  deprotonation  of  hydroxyl  group  of  the  sugar.  The  activated  5´-OH 
performs a nucleophillic attack on the γ-phosphate of ATP (donor) enabling 
the transfer of the phosphate group to a nucleoside (acceptor) and dNMP   18
and ADP are produced (Eriksson et al., 2002; Johansson et al., 2001). Their 
activities are regulated by feedback inhibitors, the end-product triphosphate 
of the preferred nucleoside, which binds to the active site as bisubstrates, 
occupying both acceptor and donor site of the specific dNK in question, see 
figure 9A-B (Birringer et al., 2005; Kosinska et al., 2005; Welin et al., 2005; 
Welin et al., 2004; Carnrot et al., 2003; Eriksson et al., 2002). For example: 
TK2 phosphorylates dT and the dTTP subsequently formed at later stage 
will  then  act  as  a  feedback  inhibitor  (Eriksson  et  al.,  2002;  Arner  & 
Eriksson, 1995).  
 
   Structural studies of dCK, dGK, Drosophila melanogaster dNK (DmdNK) 
and Herpes simplex virus 1 TK (HSV1-TK) revealed similar 3D-folds, and 
TK2 is also believed to exhibit a similar fold. These kinases are considered 
as  one  superfamily,  the  dNKs  (Sandrini  et  al.,  2006;  Sandrini  &  Piskur, 
2005).  The  TK1  family  shares  little  sequence  similarity  and  the  first 
structural studies of hTK1 and UpTK (Birringer et al., 2005; Welin et al., 
2004)  reveled  a  different  structure  than  the  dNK  family,  indicating  a 
different evolution origin forming another superfamily (Sandrini et al., 2006; 
Sandrini  &  Piskur,  2005).  However,  both superfamilies share a common 
phosphate-binding loop motif (P-loop). Extensive studies have been done 
with all mention kinases the last few decades with the aim of understanding 
their  role  as  precursor-supplier  for  repair,  maintenance  and  DNA 
replication.  
1.6 1.6 1.6 1.6  Properties of the TK1 family Properties of the TK1 family Properties of the TK1 family Properties of the TK1 family       
The TK1 family is widely distributed in most organisms, in addition, also 
exist  in  some  viruses.  The  TK1-like  enzyme  is  strictly  pyrimidine 
nucleoside  specific and catalyzes the irreversible phosphorylation of dT to 
dTMP and uses ATP as phosphate donor and feedback inhibited by dTTP 
(Eriksson et al., 2002). In the following section, members of the TK1 family 
from bacterial and human origin will be discussed.    
1.6.1 1.6.1 1.6.1 1.6.1 Bacterial TKs Bacterial TKs Bacterial TKs Bacterial TKs              
Ongoing microbial genome sequencing projects have revealed that many 
bacterial species posses TK1 genes, but there are also many lacking them. 
The first biochemical characterized bacterial TK was from Escherichia coli (E. 
coli),  where  it  is  the  only  one  present  (Karlstrom,  1970).  From  a 
phylogenetic point of view TK1-like enzymes can be arranged into two 
separate groups; Group 1 containing gram positive bacteria and eukaryotic   19
TK1s,  while  group  2  is  categorized  as  TKs  from  gram  negative bacteria 
(Sandrini et al., 2006).  Several conserved amino acids and motifs in gram 
negative  TKs are different e.g. serine substitutions in the P-loop, cystein 
residues in the magnesium binding motif and loss of an amino acid in one of 
the zink motifs upstream of the lasso loop (figure 6).  
 
Figure  6.  Multiple  sequence  alignment  of  different  TK  sequences  from  gram  positive 
bacteria Ureaplasma parvum (Up) (gi|13358159), Bacillus anthracis (Ba), human (gi|339719), 
Vaccinia  virus  (Vv)  (gi|47088414)  and  gram  negative  bacterium  Escherichia  coli.  (E.coli) 
(gi|16129199). The P-loop, Mg-binding, Zn-binding, KEN motifs and UpTK Cys183 are 
boxed.    Triangles  indicates  residues  forming  main  chain  hydrogen  bonds  with  the 
nucleoside, “*”identical residues in that column in all sequences in the alignment column, 
“:” conserved substitution and “.”  semi-conserved substitution.   
The starting methionine is always located nine residues upstream of the P-
loop in group 2, while there is variation in group 1. The implication of 
these changes remains unclear because no structure is available for group 2 
TK1. However, it is expected that this group share the same overall fold, 
but many differences are probably found in the subunit-subunit interactions 
and kinetic parameters (Sandrini et al., 2006). 
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   TKs from Ureaplasma parvum (UpTK) and Bacillus anthracis (BaTK) have 
been cloned, purified and characterized (Carnrot et al., 2006; Carnrot et al., 
2003). UpTK shares only 29 % sequence identity with hTK1 and 44 % with 
BaTK. They all share similar enzymatic properties with hTK1 despite the 
amino  acid  differences,  e.g.  they  only  phosphorylate  dT  and  dU  of  the 
natural substrates. All are feedback inhibited by the end-product dTTP, but 
there  are  some  properties  of  UpTK  that  are  different,  which  involves 
sensitivity  to  salts  and  detergents  (Carnrot  et  al.,  2003).  hTK1  showed 
positive  cooperativity  with  ATP  (Munch-Petersen  et  al.,  1993),  while 
UpTK  demonstrated  classical  Michaelis-Mentan  kinetics  (Carnrot  et  al., 
2003).  This  might  indicate  that  the  subunit-subunit  interactions  in  the 
tetramer  are different than in hTK1. Despite similar substrate specificities 
between  the  TK1  enzymes,  they  exhibit  different  phosphorylation 
efficiencies  and  inhibitory  properties,  which  can  be  seen  especially  with 
certain nucleoside analogs. In this thesis we further explore substrate and 
inhibitory properties of dT analogs with 3´-substitutions to achieve a better 
understanding of the structure function relationship of this enzyme family 
(Kosinska et al., 2007; Carnrot et al., 2006; Kosinska et al., 2005).       
 
1.6.2 1.6.2 1.6.2 1.6.2 Human t Human t Human t Human thymidine kinase 1 (hTK1) hymidine kinase 1 (hTK1) hymidine kinase 1 (hTK1) hymidine kinase 1 (hTK1)       
The hTK1 gene is located on chromosome 17 (Petty et al., 1996) encoding 
a polypeptide of 234 amino acids representing a molecular weight of 25,5 
kDa (Munch-Petersen et al., 1991).  It accepts only the natural nucleosides 
dT and dU as substrates. hTK1 uses all nucleoside triphosphates as donors 
except the feedback inhibitor dTTP, and ATP and dATP are the favored 
donors  (Eriksson  et  al.,  2002).  TK  deficient  mice  are  viable,  but  have 
increased  mutational  rates,  abnormal  immune  system  and  develop  a  fatal 
kidney disease for unknown reason (Dobrovolsky et al., 2003). TK1 activity 
is virtually absent in resting cells, but the expression level is highest in late 
G1, early S-phase cells and then drops to almost undetectable levels at the 
end of mitosis (Sherley & Kelly, 1988). This cell cycle regulation was not 
seen with the other human dNKs. It was showed that the degradation of 
hTK1 occurs through an ubiquitin ligase complex APC/C-Cdh1 targeting 
hTK1 by recognizing a KEN-box located within the last thirty residues of 
the C-terminal (Ke & Chang, 2004). This motif is absent in bacteria and 
viral-TK sequences explaining their shorter C-terminals (figure 6). Besides 
this posttranslational regulation, hTK1 can interchange between its dimeric 
and  tetrameric  forms  representing  low  and  high  catalytic  forms.  This 
dimer/tetramer interchange in hTK1 is most likely a fine-tuning mechanism   21
to provide a balanced supply of dTTP for DNA replication (Li et al., 2004; 
Munch-Petersen  et  al.,  1995;  Munch-Petersen  et  al.,  1993).  TK1  can 
phosphorylate several nucleoside analogs and the modification accepted are 
as follows: small modifications replacing the methyl group, such as halogens, 
ethyl, and no group at 5-position of the base are good substrates, however 
bulkier  or  more  polar  substitutions  drastically  decreases  the  activity  (Al-
Madhoun et al., 2004; Johansson & Eriksson, 1996; Munch-Petersen et al., 
1991). 
 
 
Figure 7. A) The structure composition of dT and 1-6 refers to the numbering position of 
the base and 1´-5´refers to the atom numbering of the sugar. Substitutions are done at 3´-
position of the dT-sugar, replacing the existing OH-group e.g. dT analogs tested with TK1 
involving B) AZMT and C) Compound 13 with 3´triazole-phenyl moiety.    
Substitutions  at  the  3-position  of  the  base  have  adequate  activities  (Al-
Madhoun et al., 2004). Fluctuating activities are seen with 3´ substitutions 
in  comparison  to  dT,  e.g.    50%  for  AZT,  40%  for  ddT  (2´,3´-
dideoxythymidine) and bulkier substitutions, and 15% for AZMT (3´-azido-
methyl-dT) (figure 7B) (Al-Madhoun et al., 2004; Johansson & Eriksson, 
1996).  2´-Flouro-arabinosyl-5-iodo-dU  (FIAU) and 2´-Flouro-arabinosyl-
5methyl-dU (FMAU) are the only exceptions of arabinosyl sugars that are 
accepted by TK1 (Al-Madhoun et al., 2004). The 3´-position substitutions 
are further explored with new NAs (figure 7B-C) and taken to the next 
level  in  this  thesis  to  further  understand  activity-structure  relationship 
between TK1 from human and bacterial origin. 
A  B 
 
C 
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1.6.3 1.6.3 1.6.3 1.6.3 The 3D structures The 3D structures The 3D structures The 3D structures       of TK1 family of TK1 family of TK1 family of TK1 family       
The first structural studies of hTK1 enzymes and bacterial UpTK (Birringer 
et al., 2005; Kosinska et al., 2005; Welin et al., 2004) with the feedback 
inhibitor dTTP or dT (Kosinska et al., 2005) revealed that the active site 
was  positions  between  two  domains,  the  lasso  domain  covering  the 
substrate/dTTP  base  that  is  buried  deep  in  a  hydrophobic  pocket.  The 
Zn
2+-ion is believed to have only a structural role, which provides stability 
to the whole structure (Segura-Pena et al., 2007b; Birringer et al., 2005; 
Welin et al., 2004). All interactions with the base and sugar occurred with 
main chain hydrogen bonds in the Zink-lasso domain and the second α/β-
domain (figure 8).  
 
 
Figure  8.  A)  A  monomer  of  UpTK  with  dTTP  (2U3Z).  B)  A  Tetramer  of  hTK1 
(1W4R). 
The later domain contained six central parallel β-sheets surrounded by one 
long  α-helix  and  three  shorter  helicase  on  the  other  side.  Further 
investigations have shown that this domain is more similar to a domain in 
the  RecA  proteins  (Welin  et  al.,  2004). There is a conserved phosphate 
binding motif (P-loop), G/SXMXXGKS/T as a turn connecting β1 to α1. 
The methionine of the motif is assumed to constrain the 5´-hydroxyl of dT, 
forcing  it  to  the  catalytic  base  (Segura-Pena  et  al.,  2007b).  A  β-hairpin 
connects β2 with β3, both secondary structures together with the conserved 
magnesium binding motif DEXQF with bound Mg
2+ ion, also contained 
the catalytic glutamic acid and all are participating in the phosphate transfer 
from ATP to 5´OH-dT (figure 6 and figure 8).  
A  B 
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   During  the  catalytic  event  the  subunits  of  the  enzymes  remain  largely 
unchanged;  however  two  flexible  regions,  lasso  loop  and  P-β  hairpin 
undergo  conformational  changes  upon  acceptor  (dT)  and  donor  (ATP) 
binding. Bound dT provides binding partners for the residues of the lasso 
loop, so that it becomes visible in the structure, while the binding of ATP is 
to the P-β hairpin folding. dTTP has also the ability to organize both the 
lasso loop and part of the P-β hairpin (Kosinska et al., 2007; Segura-Pena et 
al., 2007a; Segura-Pena et al., 2007b; Birringer et al., 2005; Kosinska et al., 
2005; Welin et al., 2004). Currently no TK1-like structures with its natural 
substrates dT and ATP bound simultaneously are known. However ATP 
analogs with dT bound to TK1 revealed that the flexible regions remain the 
same as with the bound dTTP. Differences in the quaternary structure was 
observed, where the tetramer form of TK1 display a more open state when 
the  ATP site between the monomers is occupied (Kosinska et al., 2007; 
Segura-Pena et al., 2007a; Segura-Pena et al., 2007b).  
1.7 1.7 1.7 1.7  Medical interests in the salvage enzymes  Medical interests in the salvage enzymes  Medical interests in the salvage enzymes  Medical interests in the salvage enzymes        
All  organisms,  including  viruses  have  to  reproduce  their  genomes  for 
survival  and  many  studies  have  revealed  the  importance  of  functioning 
deoxyribonucleoside  salvage  enzymes.  Humans  with  deficiencies  in 
mitochondrial  dNKs  (TK2/dGK)  suffer  from  multiple-system  failure 
(Eriksson  &  Wang,  2008;  Wang  et  al.,  2005;  Saada et al., 2001). These 
enzymes are also important from a medical point of view and many drugs 
are  nucleoside  analogs  (NA)  targeting  cancers  and  viral  diseases.  NA 
performs their effects after activation by cellular dNKs from pro-forms to 
triphosphate  forms.  These  NAs  mimic  building  blocks  of  DNA  by 
impairing the metabolism and structure of nucleic acid. A typical example is 
the pro-drug AZT (Zidovudine
®), which is activated by cellular TK1 and 
blocking  this  replication  by  chain  termination  (Sperling,  1998).  Another 
example is the pro-drug Acyclovir (Zovirax
®), which is highly selective for 
Herpes virus treatment with almost no side-effects (Sheffield et al., 2003). 
Some dNKs can be used as a diagnostic marker; e.g. there is an increased 
TK1 level in sera of cancer patients indicating rapidly growing tumor cells 
(Chen  et  al.,  2008;  Ondrej  &  Lubos,  2008;  Li  et  al.,  2005).  Other 
application  of  dNKs  is  suicide  gene  therapy,  which  aims to increase the 
selectivity  of  pro-drugs  for  tumor  cells  (Niculescu-Duvaz  &  Springer, 
2005).  The  approach  is  based  on  that  tumor  cells  are  transfected  by  a 
specific  drug-activating  enzyme,  accompanied  by  supply  of  the  prodrug.   24
The  transfected  cells  will  then  be  wiped  out  by  the  cytotoxic  effects  of 
activated  prodrugs.  However,  delivery  of  the  genes  and  control  of  gene 
expression  are  currently  problems  to  be  solved  and  is  still  under 
development. Cerapro® (Ark Therapeutics) is an example of suicide gene 
therapy now in phase III trails, based on Herpes TK in an adenoviral vector 
for treatment of brain cancer (malignant glioma).  
   Fighting viruses and tumor cells with nucleoside analogs has been very 
successful, so why not use this principle to fight bacteria? This is especially 
with  the  increase  in  multi-resistant  bacteria.  Studies  with  NA  used  in 
treatment of cancers and viral infections were tested with some pathogenic 
bacteria. It was concluded that these NAs are activated by bacterial dNKs in 
a species-specific manner, e.g. adult mice were infected with a fatal dose of 
pathogenic  Streptococcus  pyogenes  and  afterwards  received  the  NA 
gemcitabine ((2',2'-difluorodeoxycytidine (dFdC)), preventing it to develop 
into a systematic infection (Sandrini et al., 2007a; Sandrini et al., 2007b). 
Thus,  nucleoside  analogs  have  a  potential  to  be  employed  as  antibiotics 
combating emerging multi-resistant bacteria.  
1.8 1.8 1.8 1.8  Computational biochemistry  Computational biochemistry  Computational biochemistry  Computational biochemistry        
Most  drug  companies  use  computational  methods  as  a  first  approach  in 
compound  screening  through  molecular  docking.  Docking  refers  to  a 
computational  method  optimizing  the  orientation  between  two 
biomolecules  (protein  and  ligand)  within  a  binding  site  by  energy 
calculations  (posing).  This  approach  is  often  followed  by  ranking 
(categorizing estimated free energy) and scoring (rough measure of the fit of 
a  ligand  into  active  site)  (Kitchen  et  al.,  2004).  Additional  data  (e.g. 
biochemical, mutational, etc.) may improve the performance and provide 
more  correct  biological explanations. In this thesis we use the molecular 
modeling  and  drug  docking  software  Arguslab  in  combination  with 
biochemical  data  to  explain  possible  sequence-structure-function 
relationship  with  3´-substituted  dT  analogs  with  the  thymidine  kinase 
structures from both bacterial and human origin. This approach is applied in 
paper 2, however a more extended application is illustrated in the 2.2.3.  
 
   Arguslab 4.0 is distributed freely for the windows platform by Planaria 
software  and  it  has  become  an  appreciated  molecular  docking  package 
mainly  because  of  its  user-friendly  interface  (Thompson,  2004;  Mark  A. 
Thompson).  Its  internal  docking  engine,  Argusdock,  approximates  an 
exhaustive search method with similarities to other docking tools such as 
DOCK and GLIDE. In addition, Arguslab also has a genetic algorithm (GA)   25
as  an  option,  which  is  another  search  technique  to  find  exact  or 
approximate solutions to optimization and search problems. However, this 
is a modified GA, called a Lamarckian genetic algorithm (LGA) handling 
both  local  and  global  searches  (Thompson,  2004;  Morris  et  al.,  1998). 
Flexible ligand docking is also possible where the ligand is described as a 
torsion tree, and grids are constructed overlying the chosen binding site. 
The  lowest  energy  poses  are  retained  and  a  final  set  of  poses undergoes 
coarse minimization, re-clustering and ranking (Thompson, 2004; Mark A. 
Thompson).  Compounds  were  drawn  with  the  program  Marvin  sketch 
from the Marvin beans package (http://www.chemaxon.com/) and Smiles 
Translator  to  produce  the  pdb-files.  Docking  and superimposition results 
were visualised with the PyMOL graphic system (DeLano Scientific).       
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2 2 2 2  Present investigations Present investigations Present investigations Present investigations       
2.1 2.1 2.1 2.1  Aim Aim Aim Aim       
The  work  done  in  this  thesis  aims  to  understand  two  bacterial  enzymes 
responsible for thymidylate synthesis in the Ureaplasma parvum. The enzymes 
include  a  thymidine  kinase  (TK)  and  a  newly  discovered  enzyme  with 
putative  TS  activity.  Synthesized  3´  substituted  thymidine  analogs  were 
tested with recombinant UpTK and human TK1 in combination molecular 
docking  for  explaining  important  differences  in  enzyme  activity.  Cloned 
UU572 rescues a thymidine auxotrophic phenotype of a TS deficient E. coli 
phenotype strain. The low sequence homology to existing TSs suggests that 
Ureaplasma  UU572  belongs  to  a  new  thymidylate  synthase  family.  This 
information  may  provide  a  platform  for  synthesis  of  new  anti-bacterial 
agents. 
 
2.2 2.2 2.2 2.2  Results and discussion Results and discussion Results and discussion Results and discussion       
Papers I-II in the appendix describes the methods used in more detail and 
will  therefore  not be described in this section. The last subchapter 2.2.3 
regarding “Computational docking analysis: AZMT docked in UpTK and 
hTK1” will be presented in more detail.  
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2.2.1 2.2.1 2.2.1 2.2.1 Identification and characterization of  Identification and characterization of  Identification and characterization of  Identification and characterization of Ureaplasma parvum Ureaplasma parvum Ureaplasma parvum Ureaplasma parvum       
thymidylate synthase (Paper I) thymidylate synthase (Paper I) thymidylate synthase (Paper I) thymidylate synthase (Paper I)       
 
Ureaplasma parvum (Up) is associated with ureathritis in adults and chronic 
lung disease diseases in neonates. Up lack de novo nucleotide synthesis genes 
and has to import all DNA/RNA precursors. The dTTP production relies 
on thymidine kinase, but also on an unknown thymidylate synthase (TS), 
which is neither a thyA nor a thyX homolog. UU572, coding for a 67.3 
kDa  protein,  rescued  the  thymidine  auxotrophic  phenotype  of  E.  coli 
(ISM612) grown on M9 minimum medium. TS activity was detected in 
extracts prepared from Up and the enzyme was partially purified. It catalyzed 
dUMP  to  dTMP  formation  when  mixed  with  5,10-
methylenetetrahydrofolate  (CH2THF),  which  acted  as  methyl  donor. 
Homologs to UU572 were also identified in the genomes of Mycoplasma 
pneumonia  (Mpn)  and  Mycoplasma  genitalium  (Mg).  Similar  to  thymidine 
kinase,  a  cell  cycle  regulated  enzyme,  time  dependent  expression  of 
Ureaplasma TS activity was observed. Extracts prepared from thyA mutant 
ISM612  carrying  UU572  plasmid  was  eluted  from  exclusion 
chromatography  in  fractions,  corresponding  to  higher  molecular  weight 
than E. coli ThyA. Antibodies against the UU572 protein recognized a clear 
~35 kDa protein in Up extracts, suggesting a proteolytic cleavage.   
 
The UU572 gene was cloned with two mutated (UGA to UGG) codons, 
preventing  protein  truncation  when  using  E.  coli  as  protein  expression 
system.  We  tried  to  express  the  recombinant  UU572  by  using  the  pET 
system with either N-terminal or C-terminal histidine tags in combination 
with  several  bacteria  hosts.  However, no UU572 protein expression was 
detected.  We suspect that the problem was due to the codon usage (76% 
A+T)  and  high  hydrophobic  amino  acid  composition  (>50%)  of  the 
UU572 protein. This combination made expression in E. coli systems not 
possible  and  may  explain  why  UU572  failed  to  complement  the  TS 
knocked mutant E. coli (x2913) strain. To overcome this problem we chose 
to express the UU572 homolog MPN358 after codon optimization. It was 
also cloned into several expression vectors and expressed in several E. coli 
hosts.  Detectable  expression  was  only  observed  with  pET32b  and  the 
Origami  (DE3)  host  strain.  Expression  optimization  resulted  in  a  soluble 
protein  and  purified  MPN358  fusion  protein  showed  TS  activity.  The 
results from this study showed that some Mollicute proteins are very difficult 
to express and study. However, codon optimization is essential to be able to 
express these types of proteins in E. coli.     29
The  low  sequence  homology  to  either  ThyX  or  ThyA  suggested  that 
Ureaplasma TS (UU572) and its homologs, belong to a new thymidylate 
synthase  family.  This  new  enzyme  class  is  an  attractive  target  for 
development of antibiotics.   
 
2.2.2 2.2.2 2.2.2 2.2.2 Synthesis of 3´ Synthesis of 3´ Synthesis of 3´ Synthesis of 3´- - - -       triazole thymydine nucleoside analogs and their us  triazole thymydine nucleoside analogs and their us  triazole thymydine nucleoside analogs and their us  triazole thymydine nucleoside analogs and their us 
as substrates for human and Ureaplasma parvum thymidine kinase  as substrates for human and Ureaplasma parvum thymidine kinase  as substrates for human and Ureaplasma parvum thymidine kinase  as substrates for human and Ureaplasma parvum thymidine kinase 
for structure for structure for structure for structure- - - -activity investigations (P activity investigations (P activity investigations (P activity investigations (Paper II) aper II) aper II) aper II)       
 
Both  thymidine  kinase  from  Up  and  humans  have  been  crystallized  and 
although the overall structures are similar, some small differences exists. The 
TK1  family  accepts  3´-substituted  dT  analogs,  such  as  AZT  with  good 
activity.  AZT  can  be  converted  to  a  closed  cyclic  form  called  triazole. 
Although antimicrobial properties were observed with triazole compounds, 
3´-triazole  dT  analogs  lack  antiviral  activity  indicating  low  activation  by 
intracellular  TK.  Thirteen  click  chemistry-synthesized  3´-triazole  dT 
analogs  were  provided  from  our  collaborators;  the  Agrofoglio  research 
group. These analogs were used for exploring the substrate and inhibition 
properties  of  hTK1  and  UpTK.  The  enzymatic  properties  were  then 
correlated  to  Arguslab-docked  structure  complexes  for  activity-structure 
relationship analysis. 
 
   In this study we show that both kinases were able to phosphorylate many 
3´-substitutions  to  some  extent  and  many  achieved  2-10  fold  higher 
efficiency with UpTK than with hTK1. Except AZT, compound 13 was 
the  best  substrate  for  both  enzymes.  The  IC50-values  for  these  analogs 
revealed that hTK1 was more inhibited by these compounds than UpTK. 
However, none of these analogs were very good inhibitors, but may serve as 
lead compounds for future drug development. Compound 13 was docked 
in  the  active  site  of  both  enzymes,  the  results  suggested  that  the  3´-
substitutions  of  1-13  may  be  positioned  in  two  different  conformations; 
conformation A, seen in UpTK; the 3´-substitution was positioned between 
the lasso loop and P-β hairpin, and part of the 3´-substitution was most 
likely exposed to solvent. In conformation B observed in hTK1; the 3´-
substitution stretched from the lasso loop through the P-β hairpin. In this 
case, there is a Tyr 61 after two additional serines 63-64 providing potential 
hydrogen donor interactions with the fluorine atom of 13. This may explain 
the increased compound selectivity for hTK1compared to UpTK. The study 
here illustrated small functional difference in the TK1 family due to residue   30
diversity in the loop and P-β hairpin. This new information may contribute 
to development of future agent against Ureaplasma and other bacteria. 
2.2.3 2.2.3 2.2.3 2.2.3 Computational  Computational  Computational  Computational docking  docking  docking  docking analysis: AZMT docked with analysis: AZMT docked with analysis: AZMT docked with analysis: AZMT docked with       Up Up Up UpTK and  TK and  TK and  TK and 
hTK1 hTK1 hTK1 hTK1active sites  active sites  active sites  active sites               
 
Small  differences  in  the  substrate  specificity  of  hTK1  and  UpTK  were 
observed  in  an  earlier  study  (Carnrot  et  al.,  2003),  particularly  with 
substitutions at the 5-position, 3-position of the base and 3´-position of the 
sugar.  The majority of the tested nucleoside analogs showed lower IC50-
values  with  hTK1  than  UpTK.  However,  the  3´-Azido-methyl 
deoxythymidine (AZMT) (figure 7B), which is an analog of the known anti 
HIV drugs AZT (Mitsuya et al., 1985), showed 6-fold lower IC50-values for 
UpTK than hTK1 (11 µM compared to 62 µM) (Kosinska et al., 2005).  
 
   The  Arguslab  program  was  used  to  dock  AZMT  into  the  available 
structures of UpTK (2UZ3), chain B, and hTK1 (1W4R), chain A. These 
structures were used because there are no TK complexes available with the 
natural  substrates  dT  and  ATP  bound  simultaneously  in  the  active  site. 
Another problem is the absence of visible lasso loops and β-p hairpins in 
several structures, but both are visible in these cases.  It is believed that the 
monomeric  TK  remain  mostly  unchanged  during  the  catalytic  process 
(Kosinska et al., 2007; Segura-Pena et al., 2007a; Segura-Pena et al., 2007b; 
Birringer et al., 2005; Kosinska et al., 2005; Welin et al., 2004). The dTTP-
TK complexes therefore represent the best structures for docking. The Mg
2+ 
ion  in  hTK1  (1W4R)  chain  A  was  adapted  from  the  hTK1  (1XBT) 
structure, because of the absence of a Mg
2+ ion. The latter hTK1 structure 
show  a  disordered  lasso  loop,  β-phosphate  hairpin and was not used for 
docking. Water molecules were removed from TK structure, because the 
TK1 family of enzymes only interact through main-chain hydrogen bonds 
with  the  substrate.  Furthermore,  the active site is buried from the direct 
access of water (Birringer et al., 2005; Welin et al., 2004). The binding site 
was defined by the coordinates of dTTP and docking settings were set to 
Argusdock  with  “high”  and  “flexible  ligand  docking”  or  set  to  the 
alternative GA docking engine with default settings.  
 
The  template  structures  in  figure  9A  and  B  illustrates  how  the feedback 
inhibitor dTTP is position within the active site of UpTK and hTK1 and 
acts as a bisubstrate analog. The Mg
2+ ion, a participant in the reaction, is in 
front  of  the  triphosphate  groups  of  dTTP.  The  triphosphate  groups  also   31
interact with the ion and enzyme amino acids, but this is not relevant for 
the present study and is not illustrated in the figures. There are only two 
hydrogen bonds between the pentose sugar and enzyme residues, involving 
the 3´-OH to Gly182 (UpTK) or Gly176 (hTK1), and 5´-OH to the Glu 
97 (UpTK) or Glu 98 (hTK1). Glu97/98 are involved in the transfer of γ-
phosphate group from donor (ATP) to the acceptor (dT), (figure 5).  
 
 
Figure 9. The 3D structure complexes of A) dTTP-UpTK1 (2UZ3) and B) dTTP-hTK1 
(1W4R) and the modeled C) AZMT-UpTK and D) AZMT-hTK1 complexes. Hydrogen 
bonds with main chain residue are indicated with red and the assumed interaction between 
AZMT and Cys 183 is illustrated with black stripes within the red dashed box.  
Kosinska et al., (2005) observed that Glu97 was slightly closer to the 5´-OH 
in dT-UpTK structure compared to dTTP-UpTK complex. The difference 
is small and is not included in this study. The base of dTTP is located in a 
hydrophobic  pocket  and  forms  three  similar  hydrogen  bonds  in  both 
enzymes; 2-OH to residues Lys 180, 3-N to Ile 178, 4-OH to Phe 128 for 
UpTK. In hTK1 the residues corresponds instead to Val 174, Val 172 and 
Phe 128 (Figure 9A and B).                        
A  C 
 
B  D 
   32
 
   The overall conformation of sugar and base of AZMT remained the same 
when docked in UpTK and hTK1, and it retained most hydrogen bonds as 
the  template  dTTP-TK1  complex.  However,  the  3´-  of  AZMT  is 
substituted with a methyl-azido moiety and this substitution abolishes the 
hydrogen bond that normally occurs with 3´-OH of dT. When analysed 
further, the azido moiety shows two interesting conformations depending 
on the amino acids in the lasso loops. UpTK lasso loop display a unique Cys 
183,  which  apparently  interacts  with  the  azido  moiety  (figure  9C).  The 
azido moiety is on the other hand in an opposite position in hTK1, in the 
space between the lasso loop and the P-β hairpin (figure 9D).            
    
   Earlier studies have shown that the azido-group has inhibitory effects on 
cystein  proteases  like  caspases,  where  it  apparently  interacting  with  the 
catalytic  cystein  (Yang  et  al.,  2008;  Le  et  al.,  2006).  A  Cys-azido  bond 
probably  explains  the  6-fold  lower  IC50-value  in  UpTK  than  hTK1 
(Kosinska  et  al.,  2005).  When  this  was  repeated,  similar  results  were 
obtained with regard to relative activities and a similar IC50-value found for 
hTK1, however, the IC50-value was about 10-fold higher (11 to 100 µM) 
with UpTK (data not shown). At present we do not know the reason for 
this  discrepancy,  but  it  is  possible  that  AZMT  has  been  converted  to 
another compound during storage. Further studies are needed to clarify this 
discrepancy.  
 
   The UpTK Cystein is unique in comparison to other TKs (figure 7) and 
is therefore interesting as a drug-target, especially with SH-group containing 
nucleoside analogs since it is possible that a disulfide bond could be formed 
and lock the UpTK lasso loop possible inactivating the enzyme.   
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3 3 3 3  General c General c General c General concluding remarks oncluding remarks oncluding remarks oncluding remarks       and  and  and  and 
future perspectives future perspectives future perspectives future perspectives       
New antibiotics are needed to keep in pace with rising bacterial resistance 
or else our future health and economic situation is at stake. Awareness of 
antibiotic resistance and acceptance for the necessary preventive measures 
can only be obtained by better information to the general public. 
 
  This thesis investigates the possibilities to use known DNA biosynthesis 
pathways  as  medical  targets.  It  concerns  two  enzymes  from  Ureaplasma 
parvum  (Up)  in  thymidylate  synthesis;  a  putative  thymidylate  synthase 
(UU572)  and  Up  thymidine  kinase  (UpTK).  In  addition,  a  human 
thymidine  kinase  1  (hTK1)  was  also  used  in  parallel  with  UpTK  for 
exploring  differences  between  them.  Expression  problems in E. coli with 
Ureaplasma/Mycoplasma  proteins  cause  serious  obstacles  to  further 
biochemical studies. However, codon optimization may facilitate Mollicute 
protein  studies.  The  discovery  of  thymidylate  synthase  (TS)  activity  in 
Ureaplasma and some Mycoplasma species, despite the absence of ThyA and 
ThyX  homologs,  demonstrates  the  existence  of  a  new  TS  family.  Once 
again nature is full of surprises.  
 
  Although UpTK and hTK1 have similar structures, small differences in the 
amino  acid  sequences  of  their  active  sites,  are  important  for  nucleoside 
analogs selectivity. Molecular docking analysis, combined with biochemical 
investigations,  demonstrates  a  valuable  approach  for  explaining  the 
structure-activity relationship of these two enzymes.  
 
  The results from the basic research described in this thesis have contributed 
to a better understanding of two Mollicute pyrimidine salvage enzymes and 
their potential as anti-Mollicute medical targets for future drug development.      34
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